Cargando…
Inhibition of HBV Expression in HBV Transgenic Mice Using AAV-Delivered CRISPR-SaCas9
The chronic production of hepatitis B viral (HBV) antigens could cause inflammation and necrosis, leading to elevation of liver enzymes from necrotic hepatocytes, hepatitis, cirrhosis, hepatocellular carcinoma, and liver failure. However, no current treatment is capable of significantly reducing HBs...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6141737/ https://www.ncbi.nlm.nih.gov/pubmed/30254645 http://dx.doi.org/10.3389/fimmu.2018.02080 |
_version_ | 1783355760871211008 |
---|---|
author | Li, Hao Sheng, Chunyu Liu, Hongbo Wang, Shan Zhao, Jiangyun Yang, Lang Jia, Leili Li, Peng Wang, Ligui Xie, Jing Xu, Dongping Sun, Yansong Qiu, Shaofu Song, Hongbin |
author_facet | Li, Hao Sheng, Chunyu Liu, Hongbo Wang, Shan Zhao, Jiangyun Yang, Lang Jia, Leili Li, Peng Wang, Ligui Xie, Jing Xu, Dongping Sun, Yansong Qiu, Shaofu Song, Hongbin |
author_sort | Li, Hao |
collection | PubMed |
description | The chronic production of hepatitis B viral (HBV) antigens could cause inflammation and necrosis, leading to elevation of liver enzymes from necrotic hepatocytes, hepatitis, cirrhosis, hepatocellular carcinoma, and liver failure. However, no current treatment is capable of significantly reducing HBsAg expression in patients. Our previous studies had confirmed the ability of CRISPR-Cas9 in disrupting HBV cccDNA. Here, to inhibit HBV expression efficiently in the mouse model of chronic HBV infection, the miniaturized CRISPR-SaCas9 system compatible with a HBV core region derived guide-RNA had been packaged in recombinant adeno-associated virus (AAV) type 8, which lowered the levels of serum HBsAg, HBeAg, and HBV DNA efficiently in HBV transgenic mice during 58 days continuous observation after vein injection. It further confirms the potential of the CRISPR-Cas9 technique for use in hepatitis B gene therapy. |
format | Online Article Text |
id | pubmed-6141737 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-61417372018-09-25 Inhibition of HBV Expression in HBV Transgenic Mice Using AAV-Delivered CRISPR-SaCas9 Li, Hao Sheng, Chunyu Liu, Hongbo Wang, Shan Zhao, Jiangyun Yang, Lang Jia, Leili Li, Peng Wang, Ligui Xie, Jing Xu, Dongping Sun, Yansong Qiu, Shaofu Song, Hongbin Front Immunol Immunology The chronic production of hepatitis B viral (HBV) antigens could cause inflammation and necrosis, leading to elevation of liver enzymes from necrotic hepatocytes, hepatitis, cirrhosis, hepatocellular carcinoma, and liver failure. However, no current treatment is capable of significantly reducing HBsAg expression in patients. Our previous studies had confirmed the ability of CRISPR-Cas9 in disrupting HBV cccDNA. Here, to inhibit HBV expression efficiently in the mouse model of chronic HBV infection, the miniaturized CRISPR-SaCas9 system compatible with a HBV core region derived guide-RNA had been packaged in recombinant adeno-associated virus (AAV) type 8, which lowered the levels of serum HBsAg, HBeAg, and HBV DNA efficiently in HBV transgenic mice during 58 days continuous observation after vein injection. It further confirms the potential of the CRISPR-Cas9 technique for use in hepatitis B gene therapy. Frontiers Media S.A. 2018-09-11 /pmc/articles/PMC6141737/ /pubmed/30254645 http://dx.doi.org/10.3389/fimmu.2018.02080 Text en Copyright © 2018 Li, Sheng, Liu, Wang, Zhao, Yang, Jia, Li, Wang, Xie, Xu, Sun, Qiu and Song. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Li, Hao Sheng, Chunyu Liu, Hongbo Wang, Shan Zhao, Jiangyun Yang, Lang Jia, Leili Li, Peng Wang, Ligui Xie, Jing Xu, Dongping Sun, Yansong Qiu, Shaofu Song, Hongbin Inhibition of HBV Expression in HBV Transgenic Mice Using AAV-Delivered CRISPR-SaCas9 |
title | Inhibition of HBV Expression in HBV Transgenic Mice Using AAV-Delivered CRISPR-SaCas9 |
title_full | Inhibition of HBV Expression in HBV Transgenic Mice Using AAV-Delivered CRISPR-SaCas9 |
title_fullStr | Inhibition of HBV Expression in HBV Transgenic Mice Using AAV-Delivered CRISPR-SaCas9 |
title_full_unstemmed | Inhibition of HBV Expression in HBV Transgenic Mice Using AAV-Delivered CRISPR-SaCas9 |
title_short | Inhibition of HBV Expression in HBV Transgenic Mice Using AAV-Delivered CRISPR-SaCas9 |
title_sort | inhibition of hbv expression in hbv transgenic mice using aav-delivered crispr-sacas9 |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6141737/ https://www.ncbi.nlm.nih.gov/pubmed/30254645 http://dx.doi.org/10.3389/fimmu.2018.02080 |
work_keys_str_mv | AT lihao inhibitionofhbvexpressioninhbvtransgenicmiceusingaavdeliveredcrisprsacas9 AT shengchunyu inhibitionofhbvexpressioninhbvtransgenicmiceusingaavdeliveredcrisprsacas9 AT liuhongbo inhibitionofhbvexpressioninhbvtransgenicmiceusingaavdeliveredcrisprsacas9 AT wangshan inhibitionofhbvexpressioninhbvtransgenicmiceusingaavdeliveredcrisprsacas9 AT zhaojiangyun inhibitionofhbvexpressioninhbvtransgenicmiceusingaavdeliveredcrisprsacas9 AT yanglang inhibitionofhbvexpressioninhbvtransgenicmiceusingaavdeliveredcrisprsacas9 AT jialeili inhibitionofhbvexpressioninhbvtransgenicmiceusingaavdeliveredcrisprsacas9 AT lipeng inhibitionofhbvexpressioninhbvtransgenicmiceusingaavdeliveredcrisprsacas9 AT wangligui inhibitionofhbvexpressioninhbvtransgenicmiceusingaavdeliveredcrisprsacas9 AT xiejing inhibitionofhbvexpressioninhbvtransgenicmiceusingaavdeliveredcrisprsacas9 AT xudongping inhibitionofhbvexpressioninhbvtransgenicmiceusingaavdeliveredcrisprsacas9 AT sunyansong inhibitionofhbvexpressioninhbvtransgenicmiceusingaavdeliveredcrisprsacas9 AT qiushaofu inhibitionofhbvexpressioninhbvtransgenicmiceusingaavdeliveredcrisprsacas9 AT songhongbin inhibitionofhbvexpressioninhbvtransgenicmiceusingaavdeliveredcrisprsacas9 |